Skip to main content
Voyageur Pharmaceuticals Ltd. logo

Voyageur Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · VM ISIN · CA92918C1014 TSXV Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2021-10-29 Regulatory Filings
Country CA Canada
Listing TSXV VM

About Voyageur Pharmaceuticals Ltd.

https://voyageurpharmaceuticals.ca/

Voyageur Pharmaceuticals Ltd. develops and supplies contrast media products for medical imaging, including CT scans and fluoroscopy. The company operates using a vertically integrated "Earth to Bottle" strategy, controlling the entire supply chain from raw mineral acquisition to finished pharmaceutical product. Voyageur owns a significant, high-purity barium sulfate resource, positioning it as a secure and sustainable supplier of pharmaceutical-grade barium sulfate, the active ingredient in its commercialized contrast agents (e.g., SmoothX® and SmoothHD® series). This vertical control aims to ensure supply security and cost competitiveness, primarily targeting the North American market. The company is also actively developing iodine-based contrast media and V-Gas® Effervescent Granules to expand its portfolio of diagnostic imaging solutions.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Regulatory Filings
2021-10-29 English
News release - English.pdf
Regulatory Filings
2021-09-14 English
Material change report - English.pdf
Regulatory Filings
2021-08-26 English
News release - English.pdf
Regulatory Filings Classification · 90% confidence The document is a press release announcing an update to the Preliminary Economic Assessment (PEA) and a new opportunity related to marketing high purity USP Barium Sulfate. It discusses progress on the PEA, product purity improvements, and future plans but does not contain actual financial statements or detailed financial data. It is an announcement of progress and plans rather than a full financial or technical report. The document length is about 5,133 characters, which is relatively short and consistent with a news release or update rather than a comprehensive report. There is no indication that this is a full Annual Report, Interim Report, or detailed Management Discussion and Analysis. It is also not a regulatory filing, earnings release, or other specific report type. Therefore, the best classification is a Regulatory Filing (RNS) as a general announcement that does not fit other categories.
2021-08-19 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the issuance of stock options and deferred share units to directors of Voyageur Pharmaceuticals Ltd. It mentions the approval of these plans at the company's AGM but does not contain any financial statements, detailed financial data, or comprehensive report content. The document is short (3762 characters) and serves as an announcement of a capital-related event (issuance of stock options and DSUs). This fits the category of Capital/Financing Update (CAP) rather than a full report or regulatory filing. There is no indication that this is a report publication announcement or a regulatory filing. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-08-12 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2021-07-26 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.